SUGAR LAND, Texas, Sept. 26, 2025 /PRNewswire/ — Deep EigenMatics, a startup developing innovative Artificial Intelligence methods for drug discovery and development, has been awarded a United States Patent for a new breakthrough invention for AI-based drug discovery and protein design. Deep EigenMatics was founded in February 2025, and has since built one of the strongest intellectual property portfolios and the most robust innovation pipeline in the AI for Drug Discovery and Development space. Since its founding earlier this year, the company has filed 15 U.S. patent applications for breakthrough inventions, of which four have already received formal Notices of Allowance from the United States Patent and Trademark Office (USPTO).
Deep EigenMatics received the current U.S. patent (US 12,424,300 B1) for inventing a two headed neural network method for jointly generating the sequence and structure of a protein, given a condition such as a target receptor. This is a significant breakthrough because proteins are characterized by both their sequence of amino acids as well as by their structure, and these together determine protein function. However, previously existing methods had primarily focused only on predicting structure from sequence, thereby missing out on a vast number of promising candidate ligands which can be generated and developed as effective drugs for many diseases.
The inventor of Deep EigenMatics’ newly patented breakthrough method is Dr. Stephen G. Odaibo, an AI expert, mathematician, computer scientist, biochemist, software engineer, and practicing physician, who is also the company’s founder and CEO. He says “Artificial Intelligence will certainly revolutionize the discovery and development of new drugs. Currently, the drug discovery process is too lengthy, too expensive, and too inefficient, costing on average $2.6 Billion and 10 to 15 years to get a single drug to market. Each year, $300 Billion is spent worldwide on pharmaceutical research, yet the results are unsatisfactory and patients are suffering. This is a big problem that AI can help solve,” Odaibo says.
During Dr. Odaibo’s medical training — and after training as a mathematician — he spent two years in a preclinical “wet” laboratory, the Lefkowitz Lab, where he worked closely with Dr. Robert J. Lefkowitz who went on to win the 2012 Nobel Prize in Chemistry for elucidating the role of G-Protein Coupled Receptors as targets for drug therapies. That integrally biological perspective is essential. Odaibo says current AI methods, however, fall short because they are typically oversimplifications that do not adequately recognize or account for the actual biology of cellular function. “Our uniquely integrated interdisciplinary approach at Deep EigenMatics addresses this critical gap in the AI-based Drug Discovery field, and has enabled us to rapidly make a series of breakthrough innovations that we fully expect to yield positive high impact results in clinical trials.”
Deep EigenMatics has initiated the use of its proprietary drug discovery platform, Deep Discovery™, to begin generating candidate peptide and small molecule drug ligands for selected targets within its five therapeutic areas of interest: Cardiovascular-Renal-Metabolic, Oncology, Immunology, Neurology, and Ophthalmology. The company is in the earliest stages of discussions with large pharmaceutical companies regarding potential licensing and co-development partnership agreements. Additionally, Deep EigenMatics is extending its intellectual property portfolio worldwide, and is continuing to rapidly innovate with the goal of becoming the first company to fully achieve the promise of using AI to discover and prove cures for diseases.
ABOUT DEEP EIGENMATICS
Deep EigenMatics is a privately held AI-Based Drug Discovery and Development company founded in February 2025, and headquartered in Sugar Land, Texas. The company has developed one of the strongest intellectual property portfolios and the most robust innovation pipeline in the AI for Drug Discovery space. Its cutting-edge AI-based drug discovery methods power its Drug Discovery platform, Deep Discovery™. Deep EigenMatics has initiated the use of its proprietary drug discovery platform, Deep Discovery™, to begin generating candidate peptide and small molecule drug ligands for selected targets within its five therapeutic areas of interest: Cardiovascular-Renal-Metabolic, Oncology, Immunology, Neurology, and Ophthalmology. Deep EigenMatics aims to be the first company to fully achieve the promise of using AI to discover and prove cures for diseases. To learn more about licensing or co-development opportunities, email info@DeepEigenMatics.ai or visit www.DeepEigenMatics.ai.
SOURCE Deep EigenMatics
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…
Label-verified GaraHerb ingredient disclosures, manufacturing and policy transparency details, and what consumers searching for GaraHerb…
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES…
An informational overview examining category context, publicly available product disclosures, and what consumers often consider…
THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”)…
A 2026 informational overview of the Laughland whitening kit covering publicly available ingredient disclosures, product…